Stock PULM PULMATRIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Pulmatrix, Inc.

Equities

PULM

US74584P3010

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-24 pm EDT 		5-day change 1st Jan Change
2.02 USD 0.00% Intraday chart for Pulmatrix, Inc. -3.34% +8.61%
Mar. 28 Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Mar. 13 Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pulmatrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Pulmatrix, Inc. Approves Termination of Margaret Wasilewski as Chief Medical Officer
CI
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment and Closing the Study, in Agreement With Partner Cipla, to Preserve Cash and Facilitate Pursuit of Strategic Alternatives
AQ
Pulmatrix Explores Strategic Alternatives
CI
Pulmatrix Closes Study Of Fungal Lung Infection Treatment, Explores Strategic Alternatives
DJ
Pulmatrix, Inc. Enters into Further Amendment to Its Agreement with Cipla for the Development of PUR1900 in the Treatment of Allergic Bronchopulmonary Aspergillosis
CI
Pulmatrix Announces Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Pulmatrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (PULM) PULMATRIX Posts Q3 Revenue $1.8M
MT
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100 to Treat Acute Migraine
AQ
Pulmatrix Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
AQ
Pulmatrix, Inc. Announces Publication on Physiologically Based Pharmacokinetic Modelling of Potential Drug-Drug Interactions with PUR1900, Orally Inhaled Itraconazole
CI
Pulmatrix Announces Second Quarter 2023 Financial Results and Provides Corporate Update
AQ
Pulmatrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Earnings Flash (PULM) PULMATRIX Reports Q2 Revenue $1.8M
MT
Pulmatrix Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
AQ
Sector Update: Health Care Stocks Easing Late Tuesday
MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon
MT
Pulmatrix Seeks FDA Approval to Launch Phase 2 Trial of Investigational Drug for Acute Migraine Treatment; Shares Rise
MT
Pulmatrix, Inc. Announces Submission of IND Application to FDA to Initiate a Phase 2 Trial of Investigational Drug PUR3100 to Treat Acute Migraine
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PULM Stock
  4. News Pulmatrix, Inc.